‘COVID arm’ rash seen after Moderna vaccine annoying but harmless, doctors say
An angry red rash being called ‘COVID arm’ is showing up as a harmless but annoying response in some people who get the Moderna vaccine.
Related Articles
Physician unions skyrocket in two years: 6 notes
Discover the rising trend of physician unionization, with 72,000 physicians currently unionized and a significant increase in union drives in the past two year
BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints
Evan David Seigerman, BMO managing director, joins ‘Fast Money’ to discuss Novo sinking on its obesity drug data.
A roadmap to better health in the USA
On Jan 20, 2025, the Trump administration will take charge at a crucial time for health in the USA. To address the seriousness of the…
A Population Based Study of Bariatric Surgery in Illinois
Utilization of metabolic and bariatric surgery has increased significantly over the last two decades, yet barriers to access remain.
Assessment and medical management of weight regain after adolescent metabolic and bariatric surgery: a narrative review
Metabolic and bariatric surgery (MBS) in adolescents results in durable treatment of severe obesity and related complications for most. However, substantial weight regain can undermine…
Cold induces increased ad libitum energy intake independent of changes in energy expenditure: a controlled crossover trial in adults
Measures of energy metabolism [energy expenditure (EE), respiratory exchange ratio (RER)] have been associated with ad libitum energy intake (EI) and weight gain in previous…
On Ozempic? Big Food Makers Have a New Label for You
Conagra Brands adding ‘GLP-1 friendly’ to packaging on Healthy Choice frozen meals to woo users of weight-loss drugs
Your kitchen equipment could be poisoning you. Here’s what to replace
Harmful chemicals and microplastics might not be the extra ingredients you want in your meals
Novo Nordisk Stock Crashes on Obesity Drug Data. It’s a Win for Eli Lilly.
The experimental obesity drug CagriSema disappointed investors.
Could Paying for Obesity Medications Offset Obesity Care Costs?
With the Biden administration pushing for Medicare, Medicaid coverage of GLP-1s, analysts disagree on whether it will decrease obesity costs.